Literature DB >> 29393729

Challenges and opportunities for meningococcal vaccination in the developing world.

Rouba Shaker1, Danielle Fayad1, Ghassan Dbaibo1,2.   

Abstract

Meningococcal disease continues to be a life threatening infection with high morbidity and mortality even in appropriately treated patients. Meningococcal vaccination plays a major role in the control of the disease; however, implementing vaccination remains problematic in the developing world. The objective of this review is to identify the challenges facing the use of meningococcal vaccines in the developing world in order to discuss the opportunities and available solutions to improve immunization in these countries. Inadequate epidemiologic information necessary to implement vaccination and financial challenges predominate. Multiple measures are needed to achieve the successful implementation of meningococcal conjugate vaccination programs that protect against circulating serogroups in developing countries including enhanced surveillance systems, financial support and aid through grants, product development partnerships that are the end result of effective collaboration and communication between different interdependent stakeholders to develop affordable vaccines, and demonstration of the cost-effectiveness of new meningococcal vaccines.

Entities:  

Keywords:  Meningococcus; challenges; developing countries; immunization schedule; opportunities; prevention; vaccination

Mesh:

Substances:

Year:  2018        PMID: 29393729      PMCID: PMC5989893          DOI: 10.1080/21645515.2018.1434463

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  120 in total

1.  Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis.

Authors:  I Parent du Châtelet; B D Gessner; A da Silva
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

Review 2.  Meningococcal disease in the Middle East and North Africa: an important public health consideration that requires further attention.

Authors:  Mehmet Ceyhan; Sameh Anis; Latt Htun-Myint; Robert Pawinski; Montse Soriano-Gabarró; Andrew Vyse
Journal:  Int J Infect Dis       Date:  2012-05-29       Impact factor: 3.623

Review 3.  Meningococcal Disease: Epidemiology and Early Effects of Immunization Programs.

Authors:  Marco Aurelio P Sáfadi; Eitan N Berezin; Luiza Helena F Arlant
Journal:  J Pediatric Infect Dis Soc       Date:  2014-04-25       Impact factor: 3.164

4.  Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.

Authors:  Helen Campbell; Nick Andrews; Ray Borrow; Caroline Trotter; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

Review 5.  Meningococcal B vaccination: real-world experience and future perspectives.

Authors:  Parvanè Kuhdari; Armando Stefanati; Silvia Lupi; Nicoletta Valente; Giovanni Gabutti
Journal:  Pathog Glob Health       Date:  2016-06-16       Impact factor: 2.894

6.  Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales.

Authors:  Shamez N Ladhani; Kazim Beebeejaun; Jay Lucidarme; Helen Campbell; Steve Gray; Ed Kaczmarski; Mary E Ramsay; Ray Borrow
Journal:  Clin Infect Dis       Date:  2014-11-10       Impact factor: 9.079

7.  National surveillance for meningococcal disease in Japan, 1999-2014.

Authors:  Munehisa Fukusumi; Hajime Kamiya; Hideyuki Takahashi; Mizue Kanai; Yushi Hachisu; Takehito Saitoh; Makoto Ohnishi; Kazunori Oishi; Tomimasa Sunagawa
Journal:  Vaccine       Date:  2016-06-10       Impact factor: 3.641

Review 8.  The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection.

Authors:  Ray Borrow; Pedro Alarcón; Josefina Carlos; Dominique A Caugant; Hannah Christensen; Roberto Debbag; Philippe De Wals; Gabriela Echániz-Aviles; Jamie Findlow; Chris Head; Daphne Holt; Hajime Kamiya; Samir K Saha; Sergey Sidorenko; Muhamed-Kheir Taha; Caroline Trotter; Julio A Vázquez Moreno; Anne von Gottberg; Marco A P Sáfadi
Journal:  Expert Rev Vaccines       Date:  2016-11-22       Impact factor: 5.217

9.  Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease.

Authors:  Michael Bröker; Brian Cooper; Lisa M Detora; Jeffrey J Stoddard
Journal:  Infect Drug Resist       Date:  2011-07-22       Impact factor: 4.003

10.  Invasive serogroup W Neisseria meningitidis (MenW) in Ontario, Canada shows potential clonal replacement during the period January 1, 2009 to June 30, 2016.

Authors:  R S Tsang; S L Deeks; K Wong; A Marchand-Austin; F B Jamieson
Journal:  Can Commun Dis Rep       Date:  2016-12-01
View more
  5 in total

1.  Costs of Invasive Meningococcal Disease: A Global Systematic Review.

Authors:  Bing Wang; Renee Santoreneos; Hossein Afzali; Lynne Giles; Helen Marshall
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

2.  Neisseria meningitidis: analysis of pili and LPS in emerging Brazilian strains.

Authors:  Amanda Izeli Portilho; Gabriela Trzewikoswki de Lima; Elizabeth De Gaspari
Journal:  Ther Adv Vaccines Immunother       Date:  2020-05-08

3.  Clinical diagnosis in paediatric patients at urban primary health care facilities in southern Malawi: a longitudinal observational study.

Authors:  Mtisunge Joshua Gondwe; Marc Y R Henrion; Thomasena O'Byrne; Clemens Masesa; Norman Lufesi; Queen Dube; Maureen D Majamanda; Martha Makwero; David G Lalloo; Nicola Desmond
Journal:  BMC Health Serv Res       Date:  2021-02-15       Impact factor: 2.655

4.  Influenza or Meningococcal Immunization During Pregnancy and Mortality in Women and Infants: A Pooled Analysis of Randomized Controlled Trials.

Authors:  Dayna R Clark; Saad B Omer; Milagritos D Tapia; Marta C Nunes; Clare L Cutland; James M Tielsch; Niteen Wairagkar; Shabir A Madhi
Journal:  Pediatr Infect Dis J       Date:  2020-07       Impact factor: 2.129

5.  Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.

Authors:  Carmen I Baccarini; Michael W Simon; Donald Brandon; Shane Christensen; Emilia Jordanov; Mandeep S Dhingra
Journal:  Pediatr Infect Dis J       Date:  2020-10       Impact factor: 3.806

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.